Changes in local cerebral blood flow by neuroactivation and vasoactivation in patients with impaired cognitive function

European Journal of Nuclear Medicine

Volumn 23, Issue 8, 1996, Pages 878-888

  Knapp, Wolfram H ^a   Dannenberg, Claudia ^a   Marschall, Berit ^a   Zedlick, Dyrk ^a   Löschmann, Katharina ^a   Bettin, Simone ^a   Barthel, Henryk ^a   Seese, Anita ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Acetazolamide; Cerebral blood flow imaging; Dementia; Neuroactivation; Technetium 99m hexamethylpropylene amine oxime

Indexed keywords

ACETAZOLAMIDE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD VESSEL REACTIVITY; BRAIN BLOOD FLOW; CEREBELLUM; COGNITIVE DEFECT; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; INNER EAR; MAJOR CLINICAL STUDY; MALE; PARIETAL LOBE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL LOBE;

EID: 0029756587     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01084360     Document Type: Article

References (54)

1. Holman BL. Perfusion and receptor SPECT in the dementias - George Taplin Memorial Lecture. J Nucl Med 1986; 27: 855-860.
2. Holman BL, Johnson KA, Gerada B, Carvalho PA, Satlin A. The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT. J Nucl Med 1992; 33:181-185.
3. Gemmell HG, Sharp PF, Besson JAO, Crawford JR, Ebmeier KP, Davidson J, Smith FW. Differential diagnosis in dementia using the cerebral blood flow agent Tc-99m HMPAO: a SPECT study. J Comput Assist Tomogr 1987; 11: 398-402.
4. Burns A, Philpot MP, Costa DC, Ell PJ, Levy R. The investigation of Alzheimer's disease with single photon emission tomography. J Neurol Neurosurg Psychiatry 1989; 52: 248-253.
5. Montaldi D, Brooks DN, McColl JH, Wyper D, Patterson J, Barron E, McCulloch J. Measurements of regional cerebral blood flow and cognitive performance in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1990; 53: 33-38.
6. Neary D, Snowden JS, Mann DMA, Northen B, Goulding PJ, MacDermott N. Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry 1990; 53: 23-32.
7. Johnson KA, Kijewski MF, Becker A, Garada B, Satlin A, Holman BL. Quantitative brain SPECT in Alzheimer's disease and normal aging. J Nucl Med 1993; 34: 2044-2048.
8. Ryan DH. Misdiagnosis in dementia: comparisons of diagnostic error rate and range of hospital investigation according to medical speciality. Int J Geriatr Psychiatry 1994; 9: 141-147.
9. Hentschel F. Bildgebende Diagnostik bei dementiellen Erkrankungen. Klin Neuroradiol 1994; 4: 131-146.
10. Reed BR, Jagust WJ, Scab JP, Ober BA. Memory and regional cerebral blood flow in mildly symptomatic Alzheimer's disease. Neurology 1989; 39: 1537-1539.
11. Folstein M, Folstein S, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
13. Hachinski VC, Iliff LD, Zilkha E, DuBoulay GH, McAllister VL, Marshall J, Russel WR, Symon L. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-637.
14. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adez M, Leirer V. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983; 17: 37-49.
15. Ostwald WD, Fleischmann VM. Der Labyrinthtest. In: Nürnberger Altersinventar Manual (NAI). Göttingen Bern Toronto: Hogrefe; 1995: 64-82.
16. Soundy RG, et al. The radiation dosimetry of Tc-99m-exametazime. Nucl Med Commun 1990; 11: 791-799.
17. O'Mahony D, Coffey J, Murphy J, O'Hare N, Hamilton D, Freyne P, Bernard Walsh J, Coakley D. The discriminant value of semiquantitative SPECT data in mild Alzheimer's disease. J Nucl Med 1994; 35: 1450-1455.
18. Pearson R, Powell T. The neuroanatomy of Alzheimer's disease. Rev Neurosci 1989; 2: 101-122.
19. Jobst KA, Smith AD, Shepstone BJ, et al. Ante mortem diagnosis of Alzheimer's disease using a combination of CT scan and SPET scan measures: a study with post mortem confirmation. Eur J Nucl Med 1992; 19: 616.
20. Habert MO, Spampinato U, Mas JL, et al. A comparative technetium 99m hexamethylpropylene amine oxime SPET study in different types of dementia. Eur J Nucl Med 1991; 18: 3-11.
21. Perani D, DiPiero V, Vallar G, et al. Technetium-99m-HMPAO-SPECT study of regional cerebral perfusion in early Alzheimer's disease. J Nucl Med 1988; 29: 1507-1514.
22. Sharp P, Gemmell G, Cherryman G, Besson J, Crawford J. Application of iodine-123-labeled isopropylamphetamine imaging to the study of dementia. J Nucl Med 1986; 27: 761-768.
23. Frackowiak RSJ, Herold S, Petty RK, Morgan-Hughes JA. The cerebral metabolism of glucose and oxygen measured with positron tomography in patients with mitochondrial diseases. Brain 1988; 111: 1009-1024.
24. Neary D, Snowden JS, Shields RA, Burjan AWI, Northen B, MacDermott N, Prescott MC, Testa HJ. Single photon emission tomography using 99mTc-HMPAO in the investigation of dementia. J Neurol Neurosurg Psychiatry 1987; 50: 1101-1109.
25. Elmstahl S, Siennicki-Lantz A, Bjunö L. A study of regional cerebral blood flow using Tc-99m-HMPAO SPECT in elderly women with senile dementia of Alzheimer's type. Dementia 1994; 5: 302-309.
26. Battistin L, Pizzolato G, Dam M, Ponza I, Borsato N, Zanco PL, Ferlin G. Regional cerebral blood flow study with Tc-99m-hexamethylpropyleneamine oxime single photon emission computed tomography in Alzheimer's and multi-infarct dementia. Eur Neurol 1990; 30: 296-301.
27. Perlmutter JS, Powers WJ, Herscovitch P, Fox PT, Raichle ME. Standardized mean regional method for calculating global positron emission tomographic measurements. J. Cereb Blood Flow Metab 1985; 5: 476-480.
28. Perlmutter JS, Powers WJ, Hersovitch P, Fox PT, Raichle ME. Regional asymmetries of cerebral blood flow, blood volume, and oxygen utilization and extraction in normal subjects. J Cereb Blood Flow Metab 1987; 7: 64-67.
29. Englund E, Brun A, Ailing C. White matter changes in dementia of Alzheimers type - biochemical and neuropathological correlates. Brain 1988; 111: 1425-1429.
30. Janota I, Mirsen TR, Hachinski VC, Lee DH, Merskey H. Neuropathologic correlates of leuko-araiosis. Arch Neurol 1989; 46: 1124-1128.
31. Scheibel AB, Duong T, Tomiyasu U. Denervation microangiopathy in senile dementia. Alzheimer type. Alzheimer Dis Assoc Disord 1987; 11: 19-37.
32. Johnson KA, Davis KR, Buonanno FS, Brady TJ, Rosen TJ, Growdon JH. Comparison of magnetic reasonance and roentgen ray computed tomography in dementia. Arch Neurol 1987; 44: 1075-1080.
33. Kozachuk WE, DeCarli C, Schapiro MB, Wagner EE, Rapoport SI, Horowitz B. White matter hyperintensities in dementia of Alzheimer's type and in healthy subjects without cerebrovascular risk factors. A magnetic resonance imaging study. Arch Neurol 1990; 47: 1306-1310.
34. Schmidt R. Comparison of magnetic resonance imaging in Alzheimer's disease, vascular dementia and normal aging. Eur Neurol 1992; 32: 164-169.
35. Knop J, Thie A, Fuchs C, Siepmann G, Zeumer H. Tc-99m-HMPAO-SPECT with acetazolamide challenge to detect hemodynamic compromise in occlusive cerebrovascular disease. Stroke 1992; 23: 1733-1742.
36. Sullivan HG, Kingsbury TB, Morgan ME, Jeffcoat RD, Allison JD, Goode JJ, McDonnell DE. The rCBF response to diamox in normal subjects and cerebrovascular disease patients. J Neurosurg 1987; 67: 525-534.
37. Dahl A, Lindegaard KF, Russell D, Nyberg-Hansen R, Rootwelt K, Sorteberg W, Nornes H. A comparison of transcranial Doppler and cerebral blood flow study to assess cerebral vasoreactivity. Stroke 1992; 23: 15-19.
38. Stoppe G, Schütze R, Kögler A, Staedt J, Munz D, Emrich D, Rüther E. Cerebrovascular reactivity to acetazolamide in (senile) dementia of Alzheimer's type: relationship to disease severity. Dementia 1995; 6: 73-82.
39. Bonte FJ, Devous MD, Reisch JS, Ajmani AK, Weiner MF, Hom J, Tintner R. The effect of acetazolamide on regional cerebral blood flow in patients with Alzheimer's disease or stroke as measured by single-photon emission computed tomography. Invest Radiol 1989; 24: 99-103.
40. Kuwabara Y, Ichiya Y, Otsuka M, Masuda K, Ichimiya H, Fujishima M. Cerebrovascular responsiveness to hypercapnia in Alzheimer's dementia and vascular dementia of the Binswanger type. Stroke 1992; 23: 594-598.
41. Hachinski VC, Iliff LD, Phil M, Zilhka E, DuBoulay GH, McAllister VL, Marshall J, Russell RWR, Symon L. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-637.
42. Heun R, Krämer G, Knappertz VA. Vasomotor reactivity in dementia of Alzheimer type. Int J Geriatr Psychiatry 1994; 9: 913-918.
43. Fazekas F, Alavi A, Chawluk JB, et al. Comparison of CT, MR and PET in Alzheimer's dementia and normal aging. J Nucl Med 1989; 30: 1607-1615.
44. Prohovnik G, Alexander E, Tatemichi TK, Mayeux R. Exploring the nature of the parietotemporal perfusion deficit in Alzheimer's disease. J Cereb Blood flow Metab 1991; 11: 179.
45. Weinstein HC, van Gool WA, Hijdra A, van Royen EA. Effect of cerebral atrophy on semiquantitative analysis of SPECT in Alzheimer's disease. Eur J Nucl Med 1990; 16: 523.
46. Jobst KA, Smith AD, Barker CS, Wear A, King EM, Smith A, Anslow PA, Molyneux AJ, Shepstone BJ, Soper N, Holmes KA, Robinson JR, Hope RA, Oppenheimer C, Brockbank K, McDonald B. Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer' disease. J Neurol Neurosurg Psychiatry 1992; 55: 190-194.
47. Lou HC, Edvinsson L, Mackenzie ET. The concept of coupling blood flow to brain function: Revision required? Ann Neurol 1987; 22: 289-297.
48. Miller JD, DeLeon MJ, Ferris SH, Kluger A, George AE, Reisberg B, Sachs HJ, Wolf HP. Abnormal temporal lobe response in Alzheimer's disease during cognitive processing as measured by C-11-2-deoxy-D-glucose and PET. J Cereb Blood Flow Metab 1987; 7: 248-251.
49. Buchsbaum MS, Kesslak JP, Lynch G, Chui H, Wu J, Sicotte N, Hazlette E, Teng E, Cotman CW. Temporal hippocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer's type and controls. Preliminary studies. Arch Gen Psychiatry 1991; 48: 840-847.
50. Kessler J, Herholz K, Grond M, Heiss WD. Impaired metabolic activation in Alzheimer's disease. A PET study during continuous visual recognition. Neuropsychologia 1991; 29: 229-243.
51. Frackowiak RSJ, Pozzilli C, Legg NJ. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 1981; 104: 753-778.
52. Friedland RP, Budinger TF, Ganz E. Regional cerebral metabolic alterations in dementia of the Alzheimer's type: positron emission tomography with F-18 fluorodeoxyglucose. J Comput Assist Tomogr 1986; 7: 590-598.
53. Grünwald F, Horn R, Rieker O, Klemm E, Menzel C, Möller HJ, Biersack HJ. HMPAO-SPECT bei Demenz vom Alzheimer-Typ und Major Depression mit mnestischen Störungen. Nucl Med 1993; 32: 128-133.
54. Duara R, Barker W, Chang J, Yoshii F, Loewenstein DA, Pascal S. Viability of neocortical function shown in behavioral activation state PET studies in Alzheimer disease. J Cereb Blood Flow Metab 1992; 12: 927-934.